Why are prescription drug ads even allowed in the US?
Table of Contents
Pharmaceutical ads in the United States are annoying. Absurd. And almost uniquely american. In fact, only one other high-income country in the entire world – New Zealand – allows prescription drug companies to advertise directly to consumers. Everyone else has decided the downsides aren’t worth it. So why hasn’t the U.S. stopped them?
From the get-go, health secretary Robert F.Kennedy Jr. has named eliminating pharmaceutical ads as one of his goals. And believe it or not, we’re with him on this one. (Gasp!) But can the administration actually take action? They think they can. This week, a new executive memo and an accompanying FDA press release claimed to step up enforcement against drug ads.
Here are answers to the top nine questions on the moves.
1. Why are prescription drug ads even allowed here?
The story goes back to 1938, when Congress passed the Federal Food, Drug, and Cosmetic Act. For decades afterward, most assumed this law made it illegal to advertise prescription drugs directly to consumers. Why? Because no advertisement could possibly provide a full and complete description of a drug’s benefits and risks. Thus, ads would inevitably misbrand medicines.
but in the 1980s, the Food and Drug Administration decided that wasn’t exactly true. The agency concluded that drug ads were legal as long as they included a “brief summary” of the FDA-approved drug label. That’s when glossy magazine ads took off – big splashy photos on one page, with tiny print summarizing risks on the next.
In 1997, the FDA made another pivotal decision: it clarified that drug companies could directly advertise to consumers, even if the ads didn’t include all the risks. Provided that the ads were “truthful and not misleading,” they were okay.
Why are there so many drug ads on TV? A STAT explainer
For decades,the United States and New Zealand were the only two countries in the world that allowed pharmaceutical companies to advertise prescription drugs directly to consumers. That changed in 2018 when Brazil joined the club, but the U.S. remains the biggest market for these ads by far.
But why? And what’s the impact of this constant barrage of commercials? Here’s what you need to know:
1. It wasn’t always this way
Direct-to-consumer (DTC) advertising of prescription drugs was largely prohibited by the FDA for decades. The agency worried that it would lead to people self-diagnosing and demanding drugs they didn’t need.
But in the early 1980s, the FDA began to loosen its restrictions, and in 1997, the agency issued guidance that clarified the rules for DTC ads. This opened the floodgates.
2. How much do drug companies spend on these ads?
A lot.In 1997, spending on DTC advertising totaled $550 million. By 2020,that number had ballooned to $6.5 billion. While it dipped slightly in 2021 and 2022, it’s now on the rise again, with estimates ranging from $2.1 billion to $9.6 billion. Today, drug manufacturers pour roughly $6 billion a year into these ads, most of it concentrated on top-selling brand-name drugs – and not necessarily the best brand-name drugs, either.
Another study found that fewer than one-third of the most common drugs featured in direct-to-consumer television advertising were rated as having high added value for patients.
4. Why do ads spend half the time listing side effects?
it’s required. When the FDA opened the door to TV ads in the late 1990s, they did so with strings attached. Companies had to include a “major statement” of key risks.
On top of that, drug ads must provide “fair balance,” meaning the positives and negatives have to both be presented.In practice, this usually means the first half of the commercial shows people frolicking on beaches, while the second half is a dizzying recital of warnings.
5. Are drug ads misleading?
The short answer: sometimes.
The FDA’s Office of Prescription Drug Promotion is suppose to make sure ads are accurate, not misleading, and fairly balanced. But here’s the catch: Companies don’t have to submit ads for approval before airing them. When OPDP does find problematic ads, it’s frequently enough months after they’ve gone public.
And what counts as “misleading” isn’t always straightforward. Take an ad that promotes a new sleep medicine that helps people “fall asleep quickly.” That sounds extraordinary until you learn that in the trial leading to the drug’s FDA approval, patients taking the drug fell asleep within 30 minutes, while people taking placebo fell asleep within 45 minutes. Not a big difference. Is the ad technically misleading? Hard to say.
Psychology complicates things further. Studies show that when drug risks are read aloud while soothing images play in the background,viewers are distracted from the serious facts. The ad meets the rules, but the impact on patients is another story.
6. Do these ads actually help patients?
This is a complicated question.
“`html
Balancing Corporate Power, Commercial Speech, and the Health of Our Citizens
For decades, the United States has grappled with the tension between protecting commercial speech – the expression of ideas related to economic activity – and safeguarding public health. This balance has become increasingly strained as corporate power has grown, and marketing tactics have become more sophisticated. Recent supreme Court decisions, coupled with the pervasive influence of advertising, particularly in areas like food, pharmaceuticals, and alcohol, demand a re-evaluation of how we regulate commercial speech to prioritize the well-being of our citizens. Finding a path forward requires understanding the legal framework,recognizing the harms caused by unchecked commercial influence,and exploring potential regulatory solutions.
The Legal Landscape of Commercial Speech
The First Amendment protects freedom of speech,but commercial speech receives a different level of protection than political or personal expression. The Supreme Court has established a framework for regulating commercial speech, outlined in cases like Central Hudson Gas & Electric Corp. v. Public service Commission (1980). This framework requires that a regulation on commercial speech be:
- Lawful: It must not violate other laws.
- Substantial: It must serve a substantial government interest.
- Directly Advance: It must directly advance that interest.
- Narrowly Tailored: It must be no more extensive than necessary to serve that interest.
However, the application of this framework has evolved, ofen favoring commercial interests.more recent cases, such as Sorrell v. United States (2011), have further restricted the government’s ability to regulate commercial speech, particularly when it appears to target specific messages rather than addressing broader harms. This has created a challenging surroundings for public health advocates seeking to counter misleading or harmful marketing practices.
The harms of Unchecked Commercial Influence
The current legal framework often allows corporations to market products known to be detrimental to health. This has important consequences across various sectors:
Food and Beverage Industry
Aggressive marketing of ultra-processed foods and sugary drinks contributes to rising rates of obesity, type 2 diabetes, and cardiovascular disease. CDC data shows that over 40% of adults in the United States have obesity,a condition linked to numerous health problems. Marketing frequently enough targets children and vulnerable populations, exacerbating health disparities.
Pharmaceutical Industry
Direct-to-consumer (DTC) pharmaceutical advertising, permitted in the US and New Zealand, can lead to inappropriate prescribing, increased healthcare costs, and potential adverse drug events. Studies have shown that DTC advertising can influence patients to request specific medications, even when they may not be the most appropriate treatment.
Alcohol and Tobacco Industries
Despite decades of public health campaigns highlighting the dangers of smoking and excessive alcohol consumption, these industries continue to employ sophisticated marketing strategies to attract new customers and maintain market share.These strategies frequently enough exploit loopholes in regulations and target young people.
Potential Pathways to a Better balance
Rebalancing the scales requires a multi-faceted approach that acknowledges the importance of commercial speech while prioritizing public health. Here are some potential strategies:
strengthening Regulatory Oversight
Regulatory agencies like the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) need greater authority and resources to effectively regulate commercial speech. This includes:
- Expanding the FDA’s authority over tobacco products: Allowing the FDA to regulate the marketing and labeling of all tobacco products, including e-cigarettes, is crucial.
- Restricting marketing to children: Implementing stricter regulations on advertising targeted at children, particularly for unhealthy foods and beverages.
- Enhancing FTC enforcement: Increasing the FTC’s ability to pursue deceptive advertising claims and impose meaningful penalties on companies that violate consumer protection laws.